Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member
tabling member	label

Search

1491169

	registered interest
	date	20/07/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Evusheld
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to facilitate the availability of Evusheld over the counter at pharmacies rather than by prescription from a GP.
	tabling member constituency	Ealing Central and Acton
	tabling member printed	Dr Rupa Huq
	uin	40863
	answer	answer is ministerial correction date of answer 13/10/2022 answer text <p>The decision not to procure Evusheld at this time for prevention through emergency routes is based on independent clinical advice by the multi-agency RAPID C-19 and a national expert policy working group. The decision is based on a range of evidence, including clinical trial data, in vitro analysis and emerging observational studies. RAPID C-19 monitors activity in clinical trials for emerging evidence and where treatments are proven to be clinically effective, enables access for National Health Service patients. The Chief Medical Officer for England is content that the correct process for providing clinical advice has been followed and it should now be referred to the National Institute for Health and Care Excellence for further evaluation. The Antivirals and Therapeutics Taskforce has published this analysis of evidence, which is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/rapid-c-19-oversight-group-report-to-chief-medical-officer-review-of-evusheld" target="_blank">https://www.gov.uk/government/publications/rapid-c-19-oversight-group-report-to-chief-medical-officer-review-of-evusheld</a></p><p>A letter was issued to patient groups on 5 September on the evidence and expert analysis for the decision, which is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/decision-on-evusheld-as-a-coronavirus-covid-19-treatment-letter-to-patient-groups" target="_blank">https://www.gov.uk/government/publications/decision-on-evusheld-as-a-coronavirus-covid-19-treatment-letter-to-patient-groups</a></p> answering member constituency Newark answering member printed Robert Jenrick question first answered 13/10/2022 14:51:31 answering member 4320 label Biography information for Robert Jenrick
	tabling member	4511 label Biography information for Dr Rupa Huq

1503384

	registered interest
	date	02/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Evusheld
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will publish (a) the full clinical and scientific advice that his Department received on Evusheld and (b) his Department's reasoning for its decision not to procure the drug for treatment of long covid-19.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	45044
	answer	answer is ministerial correction date of answer 27/09/2022 answer text <p>The Government has decided not to procure Evusheld for prevention through emergency routes at this time. This is a decision based on independent clinical advice by the multi-agency initiative, RAPID C-19 and a national expert policy working group. These groups considered a range of evidence, including clinical trial data, in vitro analysis and emerging observational studies and concluded there is currently insufficient evidence of benefit to recommend deployment. The Chief Medical Officer for England is content that the correct process for providing clinical advice has been followed and agree that this should now be referred to the National Institute for Health and Care Excellence for further evaluation.</p><p>The Department wrote to patient groups on 5 September 2022 with information on this decision and evidence considered. The letter summarised the evidence considered by RAPID C-19 which contributed to the decision not to procure and deploy Evusheld and detailed the next steps the Government will take. The Department intends to publish further details of the clinical advice received shortly.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 27/09/2022 15:02:05 answering member 4320 label Biography information for Robert Jenrick previous answer version 17526 answering member constituency Erewash answering member printed Maggie Throup answering member 4447
	tabling member	1506 label Biography information for Andrew Gwynne

1503413

	registered interest
	date	02/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Attention Deficit Hyperactivity Disorder: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help ensure that patients who require treatment for Attention deficit hyperactivity disorder and similar conditions will not been impacted by potential disruptions to the supply chains for the prescription medications they require.
	tabling member constituency	Leeds North West
	tabling member printed	Alex Sobel
	uin	45098
	answer	answer is ministerial correction date of answer 27/09/2022 answer text <p>The Department has well established procedures to deal with supply issues with prescription medicines and works with the Medicines and Healthcare products Regulatory Agency, NHS England and industry to prevent shortages and ensure that any risks to patients are minimised should they arise.</p><p>We are aware of supply issues with some medicines used in the treatment of attention deficit hyperactivity disorder. However, alternative products remain available and communications have been issued to the National Health Service to provide advice.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 27/09/2022 15:36:57 answering member 4320 label Biography information for Robert Jenrick
	tabling member	4658 label Biography information for Alex Sobel

1503584

	registered interest
	date	02/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs: Labelling
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the efficacy of standardising colour coding of capsules between manufacturers to help patients ensure that they are taking the correct medicine.
	tabling member constituency	St Albans
	tabling member printed	Daisy Cooper
	uin	45298
	answer	answer is ministerial correction date of answer 29/09/2022 answer text <p>Regulatory guidance published since 2015 recognises the issue of tablet colour in treatment compliance and encourages suppliers and manufacturers to produce generic versions which are visually aligned with the innovator product.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 29/09/2022 14:19:37 answering member 4320 label Biography information for Robert Jenrick
	tabling member	4769 label Biography information for Daisy Cooper

1503607

	registered interest
	date	02/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Allergies: Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the adequacy of supply of EpiPen/epinephrine; and what steps his Department takes to help ensure sufficient supply of that medication.
	tabling member constituency	Plymouth, Moor View
	tabling member printed	Johnny Mercer
	uin	45331
	answer	answer is ministerial correction date of answer 27/09/2022 answer text <p>Epipen 300 microgram pens and Epipen 150 microgram Epipens continue to be available and alternative brands of adrenaline auto-injectors also remain available.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 27/09/2022 15:33:48 answering member 4320 label Biography information for Robert Jenrick
	tabling member	4485 label Biography information for Johnny Mercer

1503863

	registered interest
	date	02/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Darent Valley Hospital
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the ONS publication entitled How the population changed in Dartford: Census 2021, published on 28 June 2022, if he will review the capacity of Darent Valley Hospital in the context of an above national average population increase in the local area in the period 2011 to 2021.
	tabling member constituency	Gravesham
	tabling member printed	Adam Holloway
	uin	45469
	answer	answer is ministerial correction date of answer 27/09/2022 answer text <p>The Health and Care Act 2022 established 42 Integrated Care Boards (ICBs) in England. ICBs empower local health and care leaders to integrate planning and provision of services and will produce five-year joint forward plans with partner National Health Service trusts and foundation trusts to respond to local health needs. This may include consideration of the needs of a changing population.</p><p>There are no current plans to review the capacity of Darent Valley Hospital. Kent and Medway ICB are responsible for planning and commissioning healthcare services, including inpatient acute and emergency and urgent care services.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 27/09/2022 15:11:51 answering member 4320 label Biography information for Robert Jenrick
	tabling member	1522 label Biography information for Adam Holloway

1504203

	registered interest
	date	02/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Immunosuppression
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help (a) improve the effectiveness of and (b) increase access to Covid-19 treatments for people with compromised immune systems.
	tabling member constituency	Chipping Barnet
	tabling member printed	Theresa Villiers
	uin	45744
	answer	answer is ministerial correction date of answer 27/09/2022 answer text <p>Currently, immunocompromised patients, who form part of the high-risk cohort are a priority group eligible for receiving novel effective COVID-19 treatments within the community following a positive test. These treatments include both antiviral drugs and neutralising monoclonal antibodies which are available via COVID Medicines Delivery Units.</p><p> </p><p>The Therapeutics Clinical Review Panel has been established to review the patient cohorts which could be eligible for COVID-19 therapies. On 30 May 2022 the Department published an Independent Advisory Group report which revised the high-risk cohort and included additional groups of patients. As a result of these changes and improved identification by the National Health Service, the cohort of eligible patients has grown to an estimated 1.8 million patients in the United Kingdom.</p><p> </p><p>Access to treatments could be extended further if evidence from clinical trials supports doing so. The PANORAMIC study which aims to improve understanding of the effectiveness antivirals in preventing hospitalisation and/or death in a largely vaccinated population. It will provide data for the NHS to determine which patient groups could benefit most from antiviral treatments.</p> answering member constituency Newark answering member printed Robert Jenrick grouped question UIN 45746 question first answered 27/09/2022 15:30:50 answering member 4320 label Biography information for Robert Jenrick previous answer version 17528 answering member constituency Erewash answering member printed Maggie Throup answering member 4447
	tabling member	1500 label Biography information for Theresa Villiers

1504205

	registered interest
	date	02/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what action he is taking to increase rapid patient access to anti-viral treatments for covid-19.
	tabling member constituency	Chipping Barnet
	tabling member printed	Theresa Villiers
	uin	45746
	answer	answer is ministerial correction date of answer 27/09/2022 answer text <p>Currently, immunocompromised patients, who form part of the high-risk cohort are a priority group eligible for receiving novel effective COVID-19 treatments within the community following a positive test. These treatments include both antiviral drugs and neutralising monoclonal antibodies which are available via COVID Medicines Delivery Units.</p><p> </p><p>The Therapeutics Clinical Review Panel has been established to review the patient cohorts which could be eligible for COVID-19 therapies. On 30 May 2022 the Department published an Independent Advisory Group report which revised the high-risk cohort and included additional groups of patients. As a result of these changes and improved identification by the National Health Service, the cohort of eligible patients has grown to an estimated 1.8 million patients in the United Kingdom.</p><p> </p><p>Access to treatments could be extended further if evidence from clinical trials supports doing so. The PANORAMIC study which aims to improve understanding of the effectiveness antivirals in preventing hospitalisation and/or death in a largely vaccinated population. It will provide data for the NHS to determine which patient groups could benefit most from antiviral treatments.</p> answering member constituency Newark answering member printed Robert Jenrick grouped question UIN 45744 question first answered 27/09/2022 15:30:50 answering member 4320 label Biography information for Robert Jenrick previous answer version 17535 answering member constituency Erewash answering member printed Maggie Throup answering member 4447
	tabling member	1500 label Biography information for Theresa Villiers

1504237

	registered interest
	date	02/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Equipment: Energy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment she has made for the implications of his policies of the potential impact of rising energy bills on those who use medical equipment in the home.
	tabling member constituency	Ilford North
	tabling member printed	Wes Streeting
	uin	45956
	answer	answer is ministerial correction date of answer 10/10/2022 answer text <p>Certain specialised NHS England services also provide rebates on energy costs for patients using home medical equipment. These arrangements are unique to the contracts or service specifications of these conditions. While there is no uniform national policy for NHS England to reimburse additional utility costs, local authorities can also provide support depending on the context.</p> answering member constituency Newark answering member printed Robert Jenrick grouped question UIN 45957 45958 45959 question first answered 10/10/2022 15:02:37 answering member 4320 label Biography information for Robert Jenrick
	tabling member	4504 label Biography information for Wes Streeting

1504238

	registered interest
	date	02/09/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Equipment: Energy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what support is available to help with the cost of running (a) ventilators, (b) feeding machines, (c) nebulisers, and (d) medical equipment in the home.
	tabling member constituency	Ilford North
	tabling member printed	Wes Streeting
	uin	45957
	answer	answer is ministerial correction date of answer 10/10/2022 answer text <p>Certain specialised NHS England services also provide rebates on energy costs for patients using home medical equipment. These arrangements are unique to the contracts or service specifications of these conditions. While there is no uniform national policy for NHS England to reimburse additional utility costs, local authorities can also provide support depending on the context.</p> answering member constituency Newark answering member printed Robert Jenrick grouped question UIN 45956 45958 45959 question first answered 10/10/2022 15:02:37 answering member 4320 label Biography information for Robert Jenrick
	tabling member	4504 label Biography information for Wes Streeting